Related search

Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy

Clinical Cancer Research
Cancer ResearchOncology
2017English

SCLE and Dermatomyositis in Anti‐PD‐1 Therapy

British Journal of Dermatology
DermatologyMedicine
2019English

P1.13-32 Comparison Between Immune-Mediated Pneumonitis and Pneumonia in Patients Treated With PD-1/PD-L1 Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Effect of Combined Anti-Pd-1 and Temozolomide Therapy in Glioblastoma

OncoImmunology
OncologyAllergyImmunology
2018English

Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2020English

Diverse Cutaneous Adverse Eruptions Caused by Anti-Programmed Cell Death-1 (PD-1) and Anti-Programmed Cell Death Ligand-1 (PD-L1) Immunotherapies: Clinical Features and Management

Therapeutic Advances in Medical Oncology
Oncology
2018English

Anti-Pd-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors by Gene-Modified T Cells

Clinical Cancer Research
Cancer ResearchOncology
2013English

Features of Prognostic Significance in Testicular Germ Cell Tumours.

Journal of Clinical Pathology
MedicineForensic MedicinePathology
1977English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy